Long COVID-19 Syndrome Clinical Trial
Official title:
Cognitive Function Analysis and qEEG Study in Long COVID-19 Syndrome Patients
Over than 30% individuals with COVID-19, including the asymptomatic ones, and around 80% of patients hospitalized with COVID-19 may experience post-COVID sequelae, which is commonly referred to as Long COVID Syndrome. This condition has ties to decreased cognitive function and may lead to neuropsychiatric disorders but still need to be studied further. Using a cross-sectional design, this study will analyze the relationship between cognitive function and neuropsychiatric disorders with brain wave activity in Long COVID patients. The investigators conducted assessments utilizing the quantitative electroencephalogram (qEEG) measurement method and interviews using instruments such as the MOCA questionnaire and Self Rating Questionnaire (SRQ). With this qEEG examination, the investigators hoped that there will be an imbalance/abnormality of brain wave activity that arises related to impaired cognitive function.
This study is aimed to analyze the cognitive function and neuropsychiatry disorders with brain wave activity using qEEG that occurs after COVID/Long Covid Syndrome. The whole procedure will run for approximately 12 weeks based on the long COVID range. The determinants of long COVID patients include: never been vaccinated, old age, comorbid, female population, and hospitalized patients. The total number of subjects with the post-COVID syndrome in the proportion test is 30 subjects. The measuring instruments used to measure the decline in cognitive function are the MOCA questionnaire and Self Rating Questionnaire (SRQ). The target population is post-COVID-19 patients with Long COVID Syndrome. The accessible population is post-COVID-19 patients who have been treated at RSCM Kiara and have regular checkups at the RSCM polyclinic with Long COVID Syndrome for 12 weeks or more. The control population is post-COVID-19 patients who managed to recover without symptoms. The Long COVID Syndrome patients who meet the inclusion criteria and have signed the consent. ;